ABSTRACT
Objectives Evidence from randomised trials on long-term blood pressure (BP) reduction from pharmacologic treatment is limited. To investigate the effects of antihypertensive drugs on long-term BP change and examine its variation over time and among people with different clinical characteristics
Design Individual participant-level data meta-analysis
Setting and data source The Blood Pressure Lowering Treatment Trialists’ Collaboration involving 51 large-scale long-term randomised clinical trials
Participants 352,744 people (42% women) with mean age of 65 years and mean baseline systolic/diastolic BP of 152/87 mmHg, of whom 18% were current smokers, 50% had cardiovascular disease, 29% had diabetes, and 72% were taking antihypertensive treatment at baseline
Intervention Pharmacological BP-lowering treatment
Outcome Difference in longitudinal changes in systolic and diastolic BP between randomised treatment arms over an average follow-up of four years
Result Drugs were effective in lowering BP, with the maximum effect becoming apparent after 12-month follow-up and with gradual attenuation towards later years. Based on measures taken ≥12 months post-randomisation, more intense BP-lowering treatment reduced systolic/diastolic BP (95% confidence interval) by −11.2 (−11.4 to −11.0)/−5.6 (−5.8 to −5.5) mmHg than less intense treatment; active treatment by −5.1 (−5.3 to −5.0)/−2.3 (−2.4 to −2.2) mmHg lower than placebo, and active arm by −1.4 (−1.5 to −1.3)/−0.6 (−0.7 to −0.6) mmHg lower than the control arm for drug class comparison trials. BP reductions were consistently observed across a wide range of baseline BP values and ages, and by sex, history of cardiovascular disease and diabetes, and prior antihypertensive treatment use.
Conclusion Pharmacological agents were effective in lowering long-term BP among individuals with a wide range of characteristics, but the net between-group reductions were modest, which is partly attributable to the intended trial goals.
- blood pressure
- antihypertensive agents
- randomised clinical trials
- meta-analysis
Competing Interest Statement
This research received support from the BHF, NIHR and Oxford Martin School; M Woodward reports personal fees from Amgen, Kyowa Kirin, and Freeline outside the submitted work; No other relationships or activities that could appear to have influenced the submitted work.
Clinical Trial
This research is based on secondary analyses of published trials.
Funding Statement
This research was funded by the British Heart Foundation (BHF) (PG/18/65/33872 and FS/19/36/34346), the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and the Oxford Martin School. The funders had no role in the design or conduct of the study, data analysis, manuscript preparation, or approval to submit for publication The views expressed are those of the authors and not necessarily those of the National Health Service, the NIHR or the Department of Health and Social Care.
This manuscript was prepared using ACCORD, ALLHAT, PEACE and SHEP Research Materials obtained from the NHLBI Biologic Specimen and Data Repository Information Coordinating Centre and does not necessarily reflect the opinions or views of the ACCORD, ALLHAT, PEACE and SHEP, or the NHLBI. We acknowledge original depositors of the ANBP data and the Australian Data Archive, and declare that those who carried out the original analysis and collection of the data bear no responsibility for the further analysis or interpretation of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The BPLTTC obtained approval to conduct this collaborative research from the Oxford Tropical Research Ethics Committee (OXTREX Reference: 545-14).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our data sharing agreements with our collaborators limit us from sharing the original data to third parties. However, a governance framework exists for collaborative projects with external research investigators.
